Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.3599
-0.0231 (-6.03%)
At close: Mar 4, 2026, 4:00 PM EST
0.3476
-0.0123 (-3.42%)
After-hours: Mar 4, 2026, 7:20 PM EST
Silo Pharma Employees
Silo Pharma had 3 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$24,034
Profits / Employee
-$1,692,263
Market Cap
4.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 1 | 50.00% |
| Dec 31, 2021 | 2 | 1 | 100.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 36 |
| Calidi Biotherapeutics | 28 |
| VivoSim Labs | 14 |
| Genprex | 13 |
| BioRestorative Therapies | 11 |
| Processa Pharmaceuticals | 10 |
| MetaVia | 9 |
| Xenetic Biosciences | 2 |
SILO News
- 9 days ago - Silo Pharma Announces Share Buyback Program - GlobeNewsWire
- 14 days ago - Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio - GlobeNewsWire
- 2 months ago - Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 - GlobeNewsWire
- 3 months ago - Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD - GlobeNewsWire
- 4 months ago - Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain - GlobeNewsWire
- 4 months ago - Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program - GlobeNewsWire
- 5 months ago - Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth - GlobeNewsWire
- 5 months ago - Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci) - GlobeNewsWire